US pharma giant Pfizer presented results from the Phase III BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback